Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

645.18 

13.11 2.1%

as of Aug 03 '20

52 Week Range:

271.37 664.64


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It also has a collaboration with Zai Lab Limited and Intellia Therapeutics, Inc. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 4.89
5.90
4.61
12.80
16.95
24.91
31.50
42.36
56.23
72.18
95.25
growth rate 20.7% -21.9% 177.7% 32.4% 47.0% 26.5% 34.5% 32.7% 28.4% 32.0%
Earnings BIT -71.95
-104.47
-222.89
414.42
713.36
798.61
1,239.34
1,330.70
2,079.60
2,534.40
2,245.00
growth rate 0.0% 0.0% 100.0% 72.1% 12.0% 55.2% 7.4% 56.3% 21.9% -11.4%
Avg.PE -20.90
-20.80
-20.80
26.32
71.94
131.07
74.86
52.24
31.54
27.54
18.45
growth rate 0.0% 0.0% 100.0% 173.3% 82.2% -42.9% -30.2% -39.6% -12.7% -33.0%
ROA -9.61
-11.41
-18.38
44.08
16.87
10.20
13.42
14.23
15.23
23.85
15.94
growth rate 0.0% 0.0% 100.0% -61.7% -39.5% 31.6% 6.0% 7.0% 56.6% -33.2%
ROE -16.63
-22.60
-43.76
86.68
26.54
15.49
20.53
22.10
22.63
32.81
21.32
growth rate 0.0% 0.0% 100.0% -69.4% -41.6% 32.5% 7.7% 2.4% 45.0% -35.0%
ROIC -16.09
-15.32
-24.93
59.43
21.85
13.65
18.37
19.85
20.84
30.30
20.14
growth rate 0.0% 0.0% 100.0% -63.2% -37.5% 34.6% 8.1% 5.0% 45.4% -33.5%
Cur. Ratio 4.55
3.28
4.40
7.37
6.01
3.31
3.59
2.56
3.82
4.47
3.67
growth rate -27.9% 34.2% 67.5% -18.5% -44.9% 8.5% -28.7% 49.2% 17.0% -17.9%
Quick Ratio 4.35
3.14
4.25
6.12
5.31
2.93
3.09
2.13
2.98
3.50
2.81
growth rate -27.8% 35.4% 44.0% -13.2% -44.8% 5.5% -31.1% 39.9% 17.5% -19.7%
Leverage 1.87
2.06
2.72
1.67
1.51
1.52
1.53
1.57
1.43
1.34
1.33
growth rate 10.2% 32.0% -38.6% -9.6% 0.7% 0.7% 2.6% -8.9% -6.3% -0.8%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 65.60
93.10
103.04
841.25
999.64
976.37
1,467.79
1,611.62
2,045.60
2,272.00
2,693.40
growth rate 41.9% 10.7% 716.5% 18.8% -2.3% 50.3% 9.8% 26.9% 11.1% 18.6%
Acct.Payable 95.63
111.35
250.90
483.49
644.11
134.98
178.20
218.20
418.10
growth rate 16.4% 125.3% 92.7% 33.2% -79.0% 32.0% 22.5% 91.6%
Cur.Assets 425.50
357.60
665.78
1,206.01
1,796.93
2,084.76
2,915.10
3,180.19
4,335.00
6,447.60
7,689.10
growth rate -16.0% 86.2% 81.1% 49.0% 16.0% 39.8% 9.1% 36.3% 48.7% 19.3%
Total Assets 741.20
1,089.40
1,323.58
2,080.49
2,951.01
3,837.67
5,609.13
6,973.47
8,764.30
11,734.50
14,805.20
growth rate 47.0% 21.5% 57.2% 41.8% 30.1% 46.2% 24.3% 25.7% 33.9% 26.2%
Cash 207.10
112.60
483.61
230.28
535.61
648.72
809.10
535.20
812.70
1,467.70
1,617.80
growth rate -45.6% 329.5% -52.4% 132.6% 21.1% 24.7% -33.9% 51.9% 80.6% 10.2%
Inventory 0.00
1.42
14.65
28.64
70.35
128.86
238.58
399.36
726.10
1,151.20
1,415.50
growth rate 931.7% 95.5% 145.7% 83.2% 85.1% 67.4% 81.8% 58.6% 23.0%
Cur.Liabilities 93.60
109.10
148.27
163.55
298.84
654.66
811.16
1,241.50
1,135.50
1,442.80
2,096.60
growth rate 16.6% 35.9% 10.3% 82.7% 119.1% 23.9% 53.1% -8.5% 27.1% 45.3%
Liabilities 344.40
561.60
837.85
835.11
998.94
1,287.42
1,954.30
2,524.22
2,620.20
2,977.20
3,715.50
growth rate 63.1% 49.2% -0.3% 19.6% 28.9% 51.8% 29.2% 3.8% 13.6% 24.8%
LT Debt 109.00
159.40
275.02
455.95
504.57
457.71
362.92
351.57
703.45
growth rate 46.2% 72.5% 65.8% 10.7% -9.3% -20.7% -3.1% 100.1%
Equity 396.80
527.80
485.73
1,245.39
1,952.08
2,550.25
3,654.84
4,449.25
6,144.10
8,757.30
11,089.70
growth rate 33.0% -8.0% 156.4% 56.7% 30.6% 43.3% 21.7% 38.1% 42.5% 26.6%
Common Shares 80.00
83.00
91.00
115.00
111.00
113.00
115.00
116.00
116.00
114.00
114.00
growth rate 3.8% 9.6% 26.4% -3.5% 1.8% 1.8% 0.9% 0.0% -1.7% 0.0%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 97.32
99.69
57.22
49.34
156.32
333.01
677.93
511.90
272.60
383.10
429.60
growth rate 2.4% -42.6% -13.8% 216.9% 113.0% 103.6% -24.5% -46.8% 40.5% 12.1%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -69.94
99.20
-141.68
-74.62
588.60
752.44
1,330.78
1,485.90
1,307.10
2,195.10
2,430.00
growth rate 100.0% -100.0% 0.0% 100.0% 27.8% 76.9% 11.7% -12.0% 67.9% 10.7%
FCF per Share -2.13
-0.04
-2.38
-1.07
2.49
4.90
5.40
7.21
6.92
14.14
17.39
growth rate 0.0% 0.0% 0.0% 100.0% 96.8% 10.2% 33.5% -4.0% 104.3% 23.0%
Sale Purchase of Stock 137.39
63.55
57.39
-168.51
-367.13
-516.63
240.21
growth rate -53.7% -9.7% -100.0% 0.0% 0.0% 100.0%
FCF -170.00
-3.00
-199.00
-124.00
427.00
410.00
653.00
961.00
1,034.00
1,812.00
2,000.00
growth rate 0.0% 0.0% 0.0% 100.0% -4.0% 59.3% 47.2% 7.6% 75.2% 10.4%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 379.30
459.10
445.82
1,378.48
2,104.75
2,819.56
4,103.73
4,860.40
5,872.20
6,710.80
7,863.40
growth rate 21.0% -2.9% 209.2% 52.7% 34.0% 45.6% 18.4% 20.8% 14.3% 17.2%
Op.Income -74.10
-97.50
-221.76
750.27
413.74
823.92
1,251.92
1,330.70
2,079.60
2,534.40
2,245.00
growth rate 0.0% 0.0% 100.0% -44.9% 99.1% 52.0% 6.3% 56.3% 21.9% -11.4%
IBT -72.00
-104.50
-222.89
414.42
696.38
761.24
1,225.10
1,329.80
2,078.50
2,553.50
2,429.10
growth rate 0.0% 0.0% 100.0% 68.0% 9.3% 60.9% 8.6% 56.3% 22.9% -4.9%
Net Income -67.80
-104.50
-221.76
750.27
413.74
338.13
636.06
895.50
1,198.50
2,444.40
2,115.80
growth rate 0.0% 0.0% 100.0% -44.9% -18.3% 88.1% 40.8% 33.8% 104.0% -13.4%
EPS -0.85
-1.26
-2.45
6.75
3.72
2.98
5.52
7.70
10.34
21.29
18.46
growth rate 0.0% 0.0% 100.0% -44.9% -19.9% 85.2% 39.5% 34.3% 105.9% -13.3%
Gross Profit 377.60
457.00
441.61
1,294.02
1,949.39
2,614.54
3,711.02
2,508.40
3,400.00
4,090.60
4,044.60
growth rate 21.0% -3.4% 193.0% 50.7% 34.1% 41.9% -32.4% 35.5% 20.3% -1.1%
R&D 398.80
489.30
529.51
625.55
859.95
1,271.35
1,620.58
2,052.30
2,075.14
growth rate 22.7% 8.2% 18.1% 37.5% 47.8% 27.5% 26.6% 1.1%

Quarterly Statements

Item Name Mar '18 Jun '19 Sep '19 Dec '19 Mar '20
Earnings BIT 591.84
315.60
738.50
710.90
700.10
growth rate -46.7% 134.0% -3.7% -1.5%
Balance Sheet Mar '18 Jun '19 Sep '19 Dec '19 Mar '20
Acct.Receivable 1,943.93
2,492.60
2,696.00
2,693.40
2,933.20
growth rate 28.2% 8.2% -0.1% 8.9%
Acct.Payable 873.83
244.00
335.60
418.10
347.80
growth rate -72.1% 37.5% 24.6% -16.8%
Cur.Assets 4,544.73
6,651.00
7,109.10
7,689.10
8,644.10
growth rate 46.4% 6.9% 8.2% 12.4%
Total Assets 9,372.70
13,173.60
13,939.30
14,805.20
15,757.50
growth rate 40.6% 5.8% 6.2% 6.4%
Cash 1,019.49
1,045.50
1,384.80
1,617.80
2,208.20
growth rate 2.6% 32.5% 16.8% 36.5%
Inventory 820.40
1,317.20
1,344.30
1,415.50
1,480.90
growth rate 60.6% 2.1% 5.3% 4.6%
Cur.Liabilities 1,265.74
1,713.10
1,765.40
2,096.60
2,055.20
growth rate 35.3% 3.1% 18.8% -2.0%
Liabilities 2,805.05
3,417.70
3,434.90
3,715.50
3,624.50
growth rate 21.8% 0.5% 8.2% -2.5%
LT Debt 704.65
growth rate
Equity 6,567.64
9,755.90
10,504.40
11,089.70
12,133.00
growth rate 48.5% 7.7% 5.6% 9.4%
Common Shares 0.11
0.10
0.10
0.10
0.10
growth rate -10.7% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '18 Jun '19 Sep '19 Dec '19 Mar '20
Capital Expenditures 79.38
94.60
121.70
139.00
170.10
growth rate 19.2% 28.7% 14.2% 22.4%
Cash Dividends
growth rate
Cash From OA 618.74
188.30
557.30
787.40
698.00
growth rate -69.6% 196.0% 41.3% -11.4%
Sale Purchase of Stock 13.43
growth rate
FCF 539.37
93.70
435.60
648.40
527.90
growth rate -82.6% 364.9% 48.9% -18.6%
Income Statement Mar '18 Jun '19 Sep '19 Dec '19 Mar '20
Sales 1,511.49
1,933.70
2,048.40
2,169.50
1,828.20
growth rate 27.9% 5.9% 5.9% -15.7%
Op.Income 567.23
315.60
738.50
710.90
700.10
growth rate -44.4% 134.0% -3.7% -1.5%
IBT 585.40
224.70
768.50
889.80
668.60
growth rate -61.6% 242.0% 15.8% -24.9%
Net Income 477.98
193.10
669.60
792.00
624.60
growth rate -59.6% 246.8% 18.3% -21.1%
EPS
growth rate
Gross Profit 1,396.59
732.90
1,158.40
1,262.50
1,027.00
growth rate -47.5% 58.1% 9.0% -18.7%
R&D 498.59
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (88.61)

YOY Growth Grade:

C (62.58)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 31.85 32.40 19.47
EPS / Growth 21.6% 19.91 8.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 36.1%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 8.9% 22.2% 22.2%
Future PE 17.72 31.89 31.89
Future EPS 46.53 147.47 147.47
Value Price
MOS %
203.82
-68.4%
1,162.42
80.2%
1,162.42
80.2%
MOS Price 101.91 581.21 581.21
IRT 15.20 9.61 9.61

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.